Novartis: Spondylitis, Ankylosing trials

The registry lists 21 Spondylitis, Ankylosing studies with Novartis as lead sponsor. 2 are open to participants now and 17 have results posted.

Phase 1 1Phase 2 4Phase 3 11Phase 4 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)Not yet recruitingNCT07737730
• Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.RecruitingNCT06905288
• Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpACompletedNCT04156620Phase 3Results posted
• Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing SpondylitisCompletedNCT03350815Phase 4Results posted
• Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)CompletedNCT03259074Phase 3Results posted
• 99mTc-rhAnnexin V-128 in Diagnosis of SpondyloarthritisTerminatedNCT03232580Phase 2Results posted
• SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritisCompletedNCT03136861Phase 3Results posted
• Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing SpondylitisCompletedNCT02896127Phase 3Results posted
• Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing SpondylitisCompletedNCT02763046Phase 4Results posted
• Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing SpondylitisCompletedNCT02750592Phase 3Results posted
• Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial SpondyloarthritisCompletedNCT02696031Phase 3Results posted
• 99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)TerminatedNCT02328027Phase 1/2Results posted
• 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing SpondylitisCompletedNCT02159053Phase 3Results posted
• 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis PatientsCompletedNCT02008916Phase 3Results posted
• Extension in AS: Sustainability of Benefits, Safety and TolerabilityCompletedNCT01863732Phase 3Results posted
• 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing SpondylitisCompletedNCT01649375Phase 3Results posted
• 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing SpondylitisCompletedNCT01358175Phase 3Results posted
• Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing SpondylitisCompletedNCT01109940Phase 2Results posted
• Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing SpondylitisCompletedNCT00809159Phase 2Results posted
• A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in BrazilTerminatedNCT06715254
• 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial SpondyloarthritisCompletedNCT05155098